Sophia Genetics, MSK Explore Global Precision Oncology Hub Through AI Partnership

Sophia Genetics and Memorial Sloan Kettering Cancer Center (MSK) signed a memorandum of understanding (MOU) to explore the creation of a precision oncology hub that would combine cancer expertise, clinical data, and artificial intelligence tools to support personalized cancer care worldwide.

The organizations announced the agreement on June 4, outlining plans for a potential joint venture focused on expanding access to precision medicine capabilities beyond a single institution. According to the announcement, the proposed hub would combine MSK's clinical and scientific expertise with Sophia Genetics' AI and analytics platform.

The companies said details of the initiative remain under discussion. If established, Sophia Genetics would serve as the AI and analytics platform provider while MSK would contribute clinical leadership and clinical data resources.

Michael Frank, Director of Digital Health Business Development at MSK, said the collaboration is intended to bring together clinical expertise, AI technologies, and automation capabilities to support precision oncology.